Cargando…
Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma
Pancreatic cancer is the one of the deadliest of all malignancies. The five year survival rate for patients with this disease is 3-5%. Thus, there is a compelling need for novel therapeutic strategies to improve the clinical outcome for patients with pancreatic cancer. Several groups have demonstra...
Autores principales: | Garcia, Patrick L., Council, Leona N., Christein, John D., Arnoletti, J. Pablo, Heslin, Marty J., Gamblin, Tracy L., Richardson, Joseph H., Bjornsti, Mary-Ann, Yoon, Karina J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806809/ https://www.ncbi.nlm.nih.gov/pubmed/24194913 http://dx.doi.org/10.1371/journal.pone.0078183 |
Ejemplares similares
-
Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
por: Liles, J S, et al.
Publicado: (2011) -
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
por: Miller, Aubrey L., et al.
Publicado: (2019) -
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020) -
Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue
por: Monsma, David J, et al.
Publicado: (2012) -
A renal cell carcinoma tumorgraft platform to advance precision medicine
por: Elias, Roy, et al.
Publicado: (2021)